Want to join the conversation?
$CELG said it has settled REVLIMID (lenalidomide) patent litigation with Natco Pharma of India. Under the deal, Natco to acquire license to sell generic lenalidomide in US without volume limitation beginning in Jan. 2026 & volume-limited entry beginning in March 2022 with anticipated mid-single-digit percentage of capsules sold in first 12 months.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)